Recommendation ID
IPG418/1
Question
NICE encourages further research on percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension. Patient selection criteria should be described clearly and reported outcome measures should include adverse events and the long-term effect of the procedure on blood pressure.
Any explanatory notes
(if applicable)
Current evidence on percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension is from limited numbers of patients, but there is evidence of efficacy in the short and medium term. There is inadequate evidence on efficacy in the long term; this is particularly important for a procedure aimed at treating resistant hypertension. The limited evidence suggests a low incidence of serious periprocedural complications, but there is inadequate evidence on long-term safety. Therefore this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.

Source guidance details

Comes from guidance
Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension
Number
IPG418
Date issued
January 2012

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No